Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pullback from what ?? stock is just 36 pennies away from all time low and regarding RSI its still in the neutral area with 59 . CLSD likely to hit $2-3 in next 2 Weeks especially with the NDA acceptance which could hit the wire anytime now . Better get shares asap this still undiscovered nano cap biotech is trading below cash and is close to FDA approval there is NO cheaper FDA play in 2019 than CLSD .
still nobody interested in this pure goldmine ?
MONSTER OPPORTUNITY here on this one which trading heavily under cash and is close to FDA approval
CLSD = Market cap $39 Mil // Cash $65 Mil //NDA acceptance IMMINENT & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 15 BAGGER GEM...UNDISCOVERED Stock trading almost 40% below Cash.
Clearside BioMedical (CLSD)
Market Cap: $40 Million
Cash: $65 Million
Price: 1.24
Shares Out: 32 Million
New Presentation
http://ir.clearsidebio.com/static-files/7edc337d-df24-4e66-b1f8-97ff01b3c9a0
Clearside Biomedical Submits New Drug Application for XIPERE™ for the Treatment of Macular Edema Associated with Uveitis
https://www.barrons.com/articles/PR-CO-20181219-911604
Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss, affecting about 350,000 patients in the U.S. and more than one million worldwide.
If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024.
next stop $2++
RALLYYYYYYYYYYYYYYYYYy
CLSD breakouts
CLSD = Market cap $39 Mil // Cash $65 Mil //NDA acceptance IMMINENT & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 15 BAGGER GEM...UNDISCOVERED Stock trading almost 40% below Cash.
https://www.barrons.com/articles/PR-CO-20181219-911604
Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss, affecting about 350,000 patients in the U.S. and more than one million worldwide.
If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024.
CLSD breakout
CLSD = Market cap $39 Mil // Cash $65 Mil //NDA acceptance IMMINENT & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 15 BAGGER GEM...UNDISCOVERED Stock trading almost 40% below Cash..lets make money toegther .GL
https://www.barrons.com/articles/PR-CO-20181219-911604
Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss, affecting about 350,000 patients in the U.S. and more than one million worldwide.
If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024.
MONSTER OPPORTUNITY here on this one trading massive below cash :
CLSD = Market cap $39 Mil // Cash $65 Mil //NDA acceptance IMMINENT & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 15 BAGGER GEM...UNDISCOVERED Stock trading almost 40% below Cash..lets make money toegther .GL
Clearside BioMedical
Market Cap: $40 Million
Cash: $65 Million
Price: 1.24
Shares Out: 32 Million
https://www.barrons.com/articles/PR-CO-20181219-911604
Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss, affecting about 350,000 patients in the U.S. and more than one million worldwide.
If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024.
load up guys before she explodes higher
great buying opp here
accumulation ongoing sp will follow soon to the upside ..
(Market cap $39 Mil) (CASH $65 Mil) NDA acceptance IMMINENT & FDA DECISION by MID YEAR for potential BLOCKBUSTER = 15 BAGGER GEM...UNDISCOVERED Stock trading almost 50% below Cash.. A LIFETIME OPPORTUNITY here guys....GL
https://www.barrons.com/articles/PR-CO-20181219-911604
Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss, affecting about 350,000 patients in the U.S. and more than one million worldwide.
If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024.
strong buy here
major breakout on the way ,,FDA acceptance imminent
HOT stock here trading significantly below cash balance , FDA acceptance expected within days with potential FDA decision in Q3 this year . Stock has very strong insider and institutional ownership .This stock is a potential 10 bagger potential play because of its super low valuation .
Clearside BioMedical (CLSD)
Market Cap $39 Million
Cash $65 Million
Price 1.23
Shares Out 32 million
Clearside Biomedical submits NDA for XIPERE in macular edema associated with uveitis
http://www.biotuesdays.com/briefs/2...pere-in-macular-edema-associated-with-uveitis
Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss, affecting about 350,000 patients in the U.S. and more than one million worldwide.
If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024.
New Presentation
http://ir.clearsidebio.com/static-files/7edc337d-df24-4e66-b1f8-97ff01b3c9a0
Product Pipeline
http://www.clearsidebio.com/programs.htm#pipeline
Largest shareholders :
Wellington Management Co. LLP 4 397 523
Hatteras Venture Partners 3 466 394
Bradford T. Whitmore, MBA 3 200 000
BlackRock Fund Advisors 1 764 105
The Vanguard Group, Inc. 1 198 301
Sphera Funds Management Ltd. 1 154 690
Rock Springs Capital Management LP 975 000
Millennium Management LLC 899 428
AWM Investment Co., Inc. 875 126
Sofinnova Ventures, Inc. 606 914
HOT stock here trading significantly below cash balance , FDA acceptance expected within days with potential FDA decision in Q3 this year . Stock has very strong insider and institutional ownership .This stock is a potential 10 bagger potential play because of its super low valuation .
Market Cap $39 Million
Cash $65 Million
Price 1.23
Shares Out 32 million
Clearside Biomedical submits NDA for XIPERE in macular edema associated with uveitis
http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis
Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss, affecting about 350,000 patients in the U.S. and more than one million worldwide.
If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024.
Largest shareholders :
Wellington Management Co. LLP 4 397 523
Hatteras Venture Partners 3 466 394
Bradford T. Whitmore, MBA 3 200 000
BlackRock Fund Advisors 1 764 105
The Vanguard Group, Inc. 1 198 301
Sphera Funds Management Ltd. 1 154 690
Rock Springs Capital Management LP 975 000
Millennium Management LLC 899 428
AWM Investment Co., Inc. 875 126
Sofinnova Ventures, Inc. 606 914
rallyyyyyyyyyyyyyyyyy $1++ cominggg
load up while its still heavily undervalued
Breakout to $1++ coming ...60 days untill FDA decision
RALLYYYYYYY FDA decision at 1 April coming closer and closer
once it gets noticed then this one will explode because of its low float
Major breakout to $1+ possible especially on good news like partner deals which could happen anytime now .
Delivra Receiving Interest for its Expertise and Technology for Use in the Cannabis and Pharma Industries
https://finance.yahoo.com/news/delivra-receiving-interest-expertise-technology-110000081.html
Delivra Corp. (TSXV: DVA - "Delivra" or the "Company"), a scientific and biotechnology company, today announced that it has recently received inquiries from a number of interested parties in relation to the Company's proprietary transdermal delivery system platform, including its proprietary applications for the cannabis and pharma industries.
As a result of these inquiries, the Company has engaged Canaccord Genuity Corp. to act as exclusive financial advisor to identify, review, analyze and explore the range of strategic and other opportunities available to the Company within the cannabis and pharma industries.
the cheapest cannabis play you can get at this time
nice takeover candidate
will do some research on it
hmm not bad
Market launch of Cannabis products expected in Q4 2019 with partner Tilray ,,,,
IntelGenx Provides Update on Cannabis-Infused VersaFilm™ Program Following Recently Proposed Amendments to the Cannabis Act....January 14, 2019
http://www.intelgenx.com/investors/press-releases/press-release-details/2019/IntelGenx-Provides-Update-on-Cannabis-Infused-VersaFilm-Program-Following-Recently-Proposed-Amendments-to-the-Cannabis-Act/default.aspx
Working with partner Tilray®, IntelGenx aims to launch oral film products in late-2019
maybe because its a NDA REsubmission you should contact that guys from biopharmcatalyst to add it on his list
Load up guys FDA approval coming closer get in to enojoy the upcoming fda run up
$1++ coming like it did on tilray deal
Nobody here whats up FDA decision on the way
get in guys before she runs higher because of upcoming FDA decision..TGT $2+ before decision and higher on approval
FDA approval coming closer its time to get some
IGXT = MC $49 M / $13 M Cash / FDA DECISION ON IN APRIL 1 /= 500%+ possible here
IGXT announced that the FDA has accepted the resubmission of 505(b)(2) new drug application (NDA) for Rizaport oral soluble film 10 mg, which is being developed for the treatment of acute migraine. The FDA has set an action date of Apr 1, 2019.
AXSM = Market Cap $70 Million / Cash $41 Million or untill Q4 2019 / Shares Out 25.3 Million / 6x Phase 3 Programs in different indications targeting very large Markets ....Stock is a pure gift at this price
New Presentation
http://media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_January_2018_r.pdf
Look good
Wednesday
Above $4 i love it ..if adcom outcome is positive then this one will fly close or above $10 guys
(LPCN)ADCOM on January 10 = 200% possible / Low Valuation of $74 million and only 21.2 million shares outstanding makes this stock attractive .
HIGH RISK Bio Stock but with significant upside potential if everything goes well . ADCOM meeting on January 10 for Lipocine´s Tlando the potential FIRST Oral product for the treatment of hypogonadism , if outcome is positive the stock will likely jump close or above $10 easily especially because of its low float more infos below and good luck
Lipocine (LPCN)
Market Cap: $74 Million
Cash: $25.7 Million
Price: $3.50
Shares Out: 21.2 Million
Latest Presentation
http://files.shareholder.com/downloads/AMDA-2BVSIV/5783990236x0x958103/2EB5BE41-D62A-4270-9634-2DAE6A0E1438/LPCN_11.08.17_long_FINAL__002_.pdf
The previously scheduled Bone, Reproductive and Urologic Drugs Advisory Committee (“BRUDAC”) meeting on January 10, 2018 to discuss the NDA for TLANDO remains unchanged.
The FDA has assigned a new Prescription Drug User Fee Act (“PDUFA”) goal date of May 8, 2018.
TLANDO™: Potential first oral TRT option
-Differentiated product targeting ~$2.0 billion established US TRT market
-Poised to meet and exceed unmet need
ADCOM on January 10 = 200% possible / Low Valuation of $74 million and only 21.2 million shares outstanding makes this stock attractive .
HIGH RISK Bio Stock but with significant upside potential if everything goes well . ADCOM meeting on January 10 for Lipocine´s Tlando the potential FIRST Oral product for the treatment of hypogonadism , if outcome is positive the stock will likely jump close or above $10 easily especially because of its low float more infos below and good luck .
Lipocine (LPCN)
Market Cap: $74 Million
Cash: $25.7 Million
Price: $3.50
Shares Out: 21.2 Million
Latest Presentation
files.shareholder.com/downloads/AMDA-2BVSIV/5783990236x0x958103/2EB5BE41-D62A-4270-9634-2DAE6A0E1438/LPCN_11.08.17_long_FINAL__002_.pdf
The previously scheduled Bone, Reproductive and Urologic Drugs Advisory Committee (“BRUDAC”) meeting on January 10, 2018 to discuss the NDA for TLANDO remains unchanged.
The FDA has assigned a new Prescription Drug User Fee Act (“PDUFA”) goal date of May 8, 2018.
TLANDO™: Potential first oral TRT option
-Differentiated product targeting ~$2.0 billion established US TRT market
-Poised to meet and exceed unmet need
finance.yahoo.com/news/lpcn-third-quarter-operational-financial-180000459.html
Summary
LPCN has resubmitted its NDA for Tlando and has been assigned both a PDUFA and AdCom date. We are optimistic that Lipocine can successfully navigate both of these regulatory requirements and obtain FDA approval. Following the anticipated approval, Lipocine will develop the required sales force and find an appropriate partner to commercialize the primary care segment over the following 90 days. Based on this timeline, first sales are anticipated to take place near mid-year 2018. Lipocine will then be able to launch its first product and shift its development efforts towards LPCN 1111 and 1107.
Top Shareholders :
Royce & Associates LP 843 142 3,98%
Mahesh V. Patel, PhD 713 112 3,36%
The Vanguard Group, Inc. 661 337 3,12%
Carlson Capital LP 500 000 2,36%
John W. Higuchi, MBA 475 248 2,24%
DLD Asset Management LP 401 295 1,89%
VHCP Management LLC 386 928 1,83%
BlackRock Fund Advisors 330 684 1,56%
Renaissance Technologies LLC 228 600 1,08%
Millennium Management LLC 193 269 0,91%
insert-text-here
insert-text-here
insert-text-here
Up she goes